Study of new drug combo for B-cell lymphoma with certain proteins
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if adding the drug Tucidinostat to standard R-CHOP chemotherapy works better than R-CHOP alone for a type of lymphoma that has high levels of two proteins (BCL2 and MYC). It aims to improve treatment outcomes for people newly diagnosed with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of lymphoma called diffuse large B-cell lymphoma that is CD20-positive and has high levels of BCL2 and MYC proteins.
- You have not had any prior treatment for this lymphoma.
- You have at least one tumor that can be seen on a PET-CT scan.
- Your lymphoma has an IPI score of 2, 3, or 4 (a measure of risk).
- You are in generally good health, as measured by an ECOG performance status of 0, 1, or 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial is testing two drugs together: GW5282 and golidocitinib. It aims to see if this combination can help people with a type of T-cell lymphoma called PTCL. The trial is for patients who have already received other treatments or where standard options are limited.
Hear when a new Double Expressor Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.